35.5 F
New York
Thursday, January 28, 2021

CytoDyn Inc (OTCMKTS:CYDY) Hits 4-Month High As Covid-19 Fear Grows

Must read

Optec International Inc (OTCMKTS:OPTI) Regains Momentum and Shares Soar

Optec International Inc (OTCMKTS:OPTI) has been in focus at different points this year among investors, and it is back in focus this...

Rolls-Royce Holding (OTCMKTS:RYCEY) Turns Volatile Amid Uncertainty

The coronavirus pandemic has brought about a lot of distress in the travel sector, and companies like Rolls Royce, which supplies engines...

Alpine 4 Technologies Ltd (OTCMKTS:ALPP) Hits New High as Market Share Grows

Monday was not a particularly great time in the markets owing to renewed fears about COVID 19, but there were some stocks...

Grayscale Ethereum Trust (ETH) (OTCMKTS:ETHE) Jumps On Crypto Hype: Is it Sustainable?

The massive rally in the cryptocurrency space has been one of the biggest stories of the year in investment circles.

The coronavirus pandemic unleashed chaos all over the world and also in the markets, however, some biotech companies working on treatments for coronavirus patients saw their stocks soar.

One such company is CytoDyn Inc (OTCMKTS:CYDY), which has been working on its product leronlimab that is meant for the treatment of such patients.

Recent Developments

On Monday, CytoDyn Inc (OTCMKTS:CYDY) went on an impressive rally and soared by as much as 20% on the back of a significant announcement from the company last week. It hit its highest level in four months and took its gains over the course of the past three weeks to 155%.

Back on December 17, the company announced that it completed its enrolment for the Phase 3 registrational study with regards to the possibility of using leronlimab as a treatment for patients with severe to critical COVID 19 symptoms. It goes without saying that it is a significant milestone for CytoDyn and the excitement among investors is understandable.

In total, the company has enrolled as many as 390 patients for this study and the data is going to be analyzed by experts over a period of 28 days. It has also been revealed that the results of the study are going to be released by CytoDyn at some point in the middle of January in 2021.

CytoDyn Inc (OTCMKTS:CYDY) has been one of the better performers this year so far and has recorded gains of as much as 246%. It is a highly impressive performance considering the fact that the wider industry grew by only 2.5% so far in 2020.

Earlier in October this year, CytoDyn continued to work on the study with the goal of hitting the primary endpoint after a review and recommendation from the DSMC (Data Safety Monitoring Committee). The DSMC provided its recommendation after going through the data related to 195 patients.

Disclosure: We hold no position in CYDY stock.

Latest article

Bombardier, Inc. (OTCMKTS:BDRBF) Uptrend at Risk: In Focus

British company Bombardier, Inc. (OTCMKTS:BDRBF) came into sharp focus among investors last week after a significant development. Major Triggers

American Battery Metals Corp (OTCMKTS:ABML) Points up on Surge of Momentum

One of the stocks to have seen a lot of action last week was that of American Battery Metals Corp (OTCMKTS:ABML) and...

Grayscale Ethereum Trust (ETH) (OTCMKTS:ETHE) Attempts To Rebound On Bullish Note

While the remarkable rally in Bitcoin has led to breathless speculation about its long term price, the recent rally in Grayscale Ethereum...

Sunhydrogen Inc (OTCMKTS:HYSR) Continues to Trend Higher on High Demand

One of the sectors to have come into significant focus among investors in recent times is the hydrogen...

Artificial Intelligence Technology Solutions (OTCMKTS: AITX) Moves Up Quickly On Solid Volume

The artificial intelligence industry has grown at a remarkable pace over the past half a decade or so and over the coming...